Chi Sheng Pharma & Biotech Co Ltd

Chi Sheng Pharma & Biotech Co., Ltd maintains a strong liquidity position, with a current ratio of 2.01 and a cash and equivalents balance of TWD 443.9 million, indicating a solid ability to meet short-term obligations. The company's liquidity FPT (free cash flow to total debt) is robust, supported by a free cash flow of TWD 85.2 million and a low long-term debt of TWD 23.9 million. The price-to-book ratio of 1.32 and a price-to-tangible-book ratio of 1.32 suggest that the company is valued in line with its tangible assets. The company's profitability is reflected in a return on equity (ROE) of 11.9% and a return on assets (ROA) of 8.48%, which are strong indicators of efficient use of equity and assets. The operating income of TWD 199.3 million and a net income of TWD 164.3 million demonstrate a healthy margin structure. The gross profit of TWD 543.7 million and a revenue of TWD 1.38 billion indicate a solid gross margin, which is in line with industry standards. Chi Sheng Pharma & Biotech Co., Ltd's revenue is distributed across various segments, including injections, oral preparations, external medicines, and consumer goods. The company's geographic exposure is primarily in domestic markets and to overseas markets, including Mainland China and Southeast Asia. The revenue concentration data does not indicate a significant reliance on any single segment or region, suggesting a diversified revenue base. The company's growth trajectory is supported by a revenue of TWD 1.38 billion and a positive free cash flow of TWD 85.2 million. The outlook for the current fiscal year and the next fiscal year is positive, with the company expected to maintain its revenue and profitability. The capital expenditure of TWD -94.5 million indicates a reduction in capital spending, which may be a strategic move to preserve cash. The risk assessment for Chi Sheng Pharma & Biotech Co., Ltd indicates a low liquidity risk and a low dilution risk. The company has no immediate filing-based liquidity or dilution flags, and the debt-to-equity ratio of 0.02 suggests a conservative capital structure. The dilution potential is low, with no significant dilution sources identified in the filings. Recent events and filings do not indicate any significant changes in the company's operations or financial position. The company's financial statements and disclosures are consistent with its historical performance, and there are no material risks or uncertainties that have been disclosed in the recent filings.